INT200585

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.39
First Reported 2006
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 3
Disease Relevance 0.61
Pain Relevance 0.14

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transmembrane transport (AVP) cell-cell signaling (AVP) response to stress (AVP)
signal transducer activity (AVP) cytosol (AVP) extracellular space (AVP)
AVP (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 21 78.24 Quite High
Catecholamine 8 5.00 Very Low Very Low Very Low
anesthesia 4 5.00 Very Low Very Low Very Low
ketamine 2 5.00 Very Low Very Low Very Low
anticonvulsant 2 5.00 Very Low Very Low Very Low
Neuropeptide 2 5.00 Very Low Very Low Very Low
potassium channel 2 5.00 Very Low Very Low Very Low
tricyclic antidepressant 2 5.00 Very Low Very Low Very Low
Inflammation 2 5.00 Very Low Very Low Very Low
ischemia 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Hyponatremia 62 88.04 High High
Heart Rate Under Development 26 59.04 Quite High
Hypotension 15 53.56 Quite High
Pressure And Volume Under Development 9 51.28 Quite High
Cirrhosis 9 50.76 Quite High
Atherosclerosis 1 38.64 Quite Low
Disease 1 37.36 Quite Low
Hypertension 2 23.84 Low Low
Endotoxemia 18 20.64 Low Low
Hemorrhage 1 12.40 Low Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Conivaptan inhibits AVP by competitively and reversibly binding to selected AVP receptors without interacting with the receptors’s active sites.
Negative_regulation (inhibits) of AVP Binding (binding) of
1) Confidence 0.39 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504060 Disease Relevance 0.50 Pain Relevance 0.14
In addition, the AVP-associated increase in PVRI was attenuated by dobutamine (p = 0.064; AVP-Dobu versus AVP group at dobutamine 10 ?
Negative_regulation (0.064) of AVP-Dobu Binding (group) of
2) Confidence 0.35 Published 2006 Journal Crit Care Section Body Doc Link PMC1751059 Disease Relevance 0.05 Pain Relevance 0
In addition, the AVP-associated increase in PVRI was attenuated by dobutamine (p = 0.064; AVP-Dobu versus AVP group at dobutamine 10 ?
Negative_regulation (0.064) of AVP Binding (group) of
3) Confidence 0.35 Published 2006 Journal Crit Care Section Body Doc Link PMC1751059 Disease Relevance 0.05 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox